Phosphorylated Tau Levels in Donated Blood
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON ·
Trial Information
Current as of September 11, 2025
Recruiting
Keywords
ClinConnect Summary
This is a laboratory, observational study at the University of Texas Health Science Center in Houston. Researchers will look at donated human plasma to find out how common elevated levels of a brain biomarker called pTau217 are in blood samples. They will measure pTau217 (and total Tau) in the plasma using a specialized nanoneedle sensor. The goal is to see whether some donated plasma might have higher levels of this biomarker and whether that could have any implications for blood transfusion safety. There is no treatment or intervention for participants, and results won’t affect patient care.
Eligible samples are de-identified plasma from healthy adult blood donors, with about 250 samples planned. Donors do not need to take any additional action beyond their routine donation; the study uses leftover samples that pass quality checks and have enough volume. No personal information will be linked to the results. The study is currently recruiting in Houston, started August 28, 2025, with primary completion expected around November 2025 and overall completion by December 2025.
Gender
ALL
Eligibility criteria
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Zhongcong Xie, M.D., Ph.D.
Principal Investigator
The University of Texas Health Science Center, Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported